The standard of care in cancer treatment is undergoing a rapid paradigm shift. For decades, the default oncological approach relied on aggressive chemotherapy designed to hit malignant cells as hard as possible. Today, clinicians are increasingly selecting therapies tailored to the distinct biology of an individual patient's tumor. Even within the same cancer type, doctors are carefully weighing recurrence risks, genetic alterations, and the probability of drug response to dictate treatment intensity and sequencing.
This strategic evolution took center stage at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, one of the world's premier cancer conferences. Held in Chicago from May 29 to June 2, ASCO 2026 showcased practice-changing research across several major malignancies, including colorectal, pancreatic, and gastric cancers, as well as lymphoma.
Notably, South Korean researchers successfully translated real-world clinical challenges in colorectal cancer into prospective clinical trials. Key investigations focused on identifying patients at high risk of relapse after surgery, optimizing treatment sequencing for metastatic disease, and more precisely selecting candidates for post-operative chemotherapy. On the global stage, attention centered on targeted therapies for historically "undruggable" mutations in pancreatic cancer, novel antibody-drug conjugates (ADCs), cell therapies, and personalized cancer vaccines.
On June 18, the Korean Cancer Study Group (KCSG) released a comprehensive review of the domestic data presented at ASCO 2026 alongside overarching global drug development trends. The core takeaway was undeniable: oncology is moving decisively away from one-size-fits-all regimens toward strategies that match interventions to individual patient risk and molecular profiles.
Colorectal Cancer: Factoring in Recurrence Risk After Surgery
Colorectal cancer data commanded significant attention due to the disease's high global burden. Even after successful surgical resection, many patients relapse because microscopic residual cells remain undetected. This underscores the urgent clinical need to identify which patients require intensive post-operative chemotherapy and who can safely bypass it.
The CLAUDIA study, led by a team under Professor Kang Min-soo at Seoul National University Bundang Hospital, tackled this issue directly. The researchers evaluated minimal residual disease (MRD)—microscopic traces of cancer undetectable by conventional imaging—by analyzing circulating tumor DNA (ctDNA) fragments in the bloodstream of patients with stage 2 and 3 colorectal cancer who underwent curative surgery. An interim analysis demonstrated that ctDNA positivity and volume serve as robust predictors of recurrence risk. Once fully validated, this biomarker-driven approach could allow clinicians to intensify adjuvant chemotherapy for high-risk patients while sparing low-risk individuals from unnecessary toxicity.
For metastatic colorectal cancer, establishing effective second-line therapies after first-line treatment failure remains a critical challenge. A study led by Professors Kim Han-sang and Ahn Jung-bae at the Yonsei Cancer Center evaluated the efficacy of combining the targeted agent aflibercept with the FOLFIRI chemotherapy regimen. The combination demonstrated comparable efficacy and a manageable safety profile regardless of whether patients had previously received bevacizumab or cetuximab as a first-line treatment, validating the regimen as a versatile subsequent option.
Conversely, other findings reinforced the reality that more intensive treatment does not universally improve outcomes. A team led by Professor Kim Ji-hyung at Gangnam Severance Hospital compared a bevacizumab-based triplet chemotherapy regimen against a standard doublet regimen in patients with unresectable, right-sided metastatic colorectal cancer. While the triplet regimen trended toward a higher objective response rate, it failed to demonstrate a statistically significant improvement in six-month progression-free survival. The study serves as a crucial reminder that escalating treatment intensity does not automatically guarantee superior clinical efficacy, highlighting the need for better patient-selection biomarkers.
Progress was also made in refining treatment criteria for early-stage disease. A study led by Professor Heo Jun-young at Asan Medical Center analyzed patients with high-risk stage 2 colon cancer harboring specific DNA mismatch repair deficiencies. The data suggested that adjuvant chemotherapy successfully reduced the risks of recurrence and death in this specific subpopulation. The findings emphasize that even within stage 2 colon cancer, post-operative strategies must be highly stratified based on individual molecular characteristics.
Cracking Pancreatic Cancer and Advancing ADCs
In global oncology, breakthroughs in targeting RAS mutations in pancreatic cancer generated substantial optimism. RAS mutations drive continuous cell growth and are prevalent in pancreatic ductal adenocarcinoma, yet the RAS protein has long been considered an incredibly difficult target to bind effectively.
The phase 3 RASolute 302 trial offered a potential turning point for metastatic pancreatic ductal adenocarcinoma. The study evaluated daraxonrasib, an oral, next-generation RAS-ON inhibitor, against standard-of-care chemotherapy in patients harboring RAS G12 mutations. Patients treated with daraxonrasib achieved a median overall survival of 13.2 months—precisely double the 6.6 months observed in the chemotherapy control group. Median progression-free survival also doubled, reaching 7.3 months compared to 3.5 months for standard chemotherapy. While regulatory approvals, reimbursement evaluations, and long-term safety reviews must still clear before routine clinical adoption, the trial provides clear evidence that directly targeting RAS can dramatically extend survival in a disease notoriously referred to as the "cancer of cancers."
Antibody-drug conjugates (ADCs) also demonstrated rapid expansion. By anchoring a cytotoxic payload to a tumor-specific antibody, ADCs deliver chemotherapy directly to malignant cells while minimizing damage to healthy tissue. ASCO 2026 highlighted a broadening spectrum of ADC targets; beyond traditional markers like HER2 and TROP2, clinical development is aggressively expanding into novel antigens such as CD56 and B7-H3. In advanced colorectal cancer, a study evaluating trastuzumab rezetecan in HER2-positive, RAS/RAF wild-type patients demonstrated a significant reduction in the risk of disease progression or death alongside superior tumor shrinkage compared to current standard regimens.
Concurrently, immunotherapy is transitioning into its next generation. While foundational checkpoint inhibitors work by unblocking the patient's existing immune response via PD-1, PD-L1, or CTLA-4 pathways, current research focuses on precision-engineered immune cells and bispecific molecules that directly tether T-cells to tumor targets. Additionally, personalized cancer vaccines designed around patient-specific tumor neoantigens have emerged as a primary pillar of modern oncology research.
"ASCO 2026 clearly illustrated that cancer care is rapidly evolving to reflect the precise molecular characteristics and recurrence risks of each individual patient," stated Ahn Jin-seok, chair of the Korean Cancer Study Group. "The multi-center trials led by South Korean investigators are exceptionally meaningful because they provide rigorous clinical evidence to resolve critical questions encountered in daily practice."
While not every study presented translates immediately into a new standard of care, the overarching trajectory showcased in Chicago is undeniable. The core objective of modern oncology has shifted away from simply delivering the strongest possible treatment toward achieving the most accurate execution. Uncovering patient-specific risks and molecular vulnerabilities is officially the defining battleground for the next generation of cancer therapeutics.
